Gilead Sciences, Inc.
GILD · Nasdaq · United States · Health Care · Pharma / Biotech / Life Sci
- Coverage
- FY2016–FY2025
- History
- 10 years
- Latest filing
- 10-K · SEC EDGAR
- Reporting
- USD
- Fiscal year end
- December
- Last updated
- Feb 2026
Headline figures
Gilead Sciences, Inc. at a glance
In FY2025, Gilead Sciences, Inc. reported revenue of USD 29,443 mn, EBITDA of USD 14,396 mn, EBITDA margin of 48.9%.
| USD mn | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 28,754 | 29,443 | |||
| EBITDA | 13,272 | 14,396 | |||
| EBITDA margin | 46.2% | 48.9% | |||
| Free cash flow | 10,305 | 9,456 | |||
| ROIC | 19.1% | 26.6% |
The full 10-year history, every line item and each formula are in the platform.
In the platform
- Stat Book — normalized and as-reported IS, BS and CF
- Up to 10 years of annual and quarterly history
- Peer benchmarking and the stock screener
- Corporate risk scorecard
- DCF model from the filed inputs
- Tearsheet and live Excel formulas